126 related articles for article (PubMed ID: 38437792)
41. Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010-2016.
Schwedhelm TM; Rees JR; Onega T; Zipkin RJ; Schaefer A; Celaya MO; Moen EL
BMC Cancer; 2020 Sep; 20(1):847. PubMed ID: 32883270
[TBL] [Abstract][Full Text] [Related]
42. Cross-Stratification and Differential Risk by Breast Cancer Index and Recurrence Score in Women with Hormone Receptor-Positive Lymph Node-Negative Early-Stage Breast Cancer.
Sestak I; Zhang Y; Schroeder BE; Schnabel CA; Dowsett M; Cuzick J; Sgroi D
Clin Cancer Res; 2016 Oct; 22(20):5043-5048. PubMed ID: 27252417
[TBL] [Abstract][Full Text] [Related]
43. Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study.
Wuerstlein R; Kates R; Gluz O; Grischke EM; Schem C; Thill M; Hasmueller S; Köhler A; Otremba B; Griesinger F; Schindlbeck C; Trojan A; Otto F; Knauer M; Pusch R; Harbeck N;
Breast Cancer Res Treat; 2019 Jun; 175(2):389-399. PubMed ID: 30796651
[TBL] [Abstract][Full Text] [Related]
44. Chemotherapy decisions and patient experience with the recurrence score assay for early-stage breast cancer.
Friese CR; Li Y; Bondarenko I; Hofer TP; Ward KC; Hamilton AS; Deapen D; Kurian AW; Katz SJ
Cancer; 2017 Jan; 123(1):43-51. PubMed ID: 27775837
[TBL] [Abstract][Full Text] [Related]
45. Validation of CTS5 Model in Large-scale Breast Cancer Population and Combination of CTS5 and Ki-67 Status to Develop a Novel Nomogram for Prognosis Prediction.
Ning L; Liu Y; He X; Han R; Xin Y; Zhao J; Liu X
Am J Clin Oncol; 2024 May; 47(5):228-238. PubMed ID: 38131531
[TBL] [Abstract][Full Text] [Related]
46. Impact of the 21-Gene Recurrence Score Assay on Treatment Decisions and Cost in Patients with Node-Positive Breast Cancer: A Multicenter Study in Quebec.
Hassan S; Younan R; Patocskai E; Provencher L; Poirier B; Sideris L; Dubé P; Mihalcioiu C; Chabot-Blanchet M; Guertin MC; Boileau JF; Robidoux A
Oncologist; 2022 Oct; 27(10):822-831. PubMed ID: 35830543
[TBL] [Abstract][Full Text] [Related]
47. Implications of the 21-gene recurrence score assay (Oncotype DX) on adjuvant treatment decisions in ER-positive early-stage breast cancer patients: experience of Kuwait Cancer Control Center.
Fayaz S; Eissa HE; Demian GA
J Egypt Natl Canc Inst; 2020 Mar; 32(1):13. PubMed ID: 32372329
[TBL] [Abstract][Full Text] [Related]
48. Prognostic Utility of Breast Cancer Index to Stratify Distant Recurrence Risk in Invasive Lobular Carcinoma.
Nunes R; Sella T; Treuner K; Atkinson JM; Wong J; Zhang Y; Exman P; Dabbs D; Richardson AL; Schnabel CA; Sgroi DC; Oesterreich S; Cimino-Mathews A; Metzger O
Clin Cancer Res; 2021 Oct; 27(20):5688-5696. PubMed ID: 34376532
[TBL] [Abstract][Full Text] [Related]
49. Association of 70-Gene Signature Assay Findings With Physicians' Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay.
Tsai M; Lo S; Audeh W; Qamar R; Budway R; Levine E; Whitworth P; Mavromatis B; Zon R; Oldham D; Untch S; Treece T; Blumencranz L; Soliman H
JAMA Oncol; 2018 Jan; 4(1):e173470. PubMed ID: 29075751
[TBL] [Abstract][Full Text] [Related]
50. Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Sestak I; Buus R; Cuzick J; Dubsky P; Kronenwett R; Denkert C; Ferree S; Sgroi D; Schnabel C; Baehner FL; Mallon E; Dowsett M
JAMA Oncol; 2018 Apr; 4(4):545-553. PubMed ID: 29450494
[TBL] [Abstract][Full Text] [Related]
51. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
[TBL] [Abstract][Full Text] [Related]
52. Initial experience with the Oncotype DX assay in decision-making for adjuvant therapy of early oestrogen receptor-positive breast cancer in Hong Kong.
Cheung PS; Tong AC; Leung RC; Kwan WH; Yau TC
Hong Kong Med J; 2014 Oct; 20(5):401-6. PubMed ID: 24948666
[TBL] [Abstract][Full Text] [Related]
53. Enhancing decision-making about adjuvant chemotherapy in early breast cancer following EndoPredict testing.
Fallowfield L; Matthews L; May S; Jenkins V; Bloomfield D
Psychooncology; 2018 Apr; 27(4):1264-1269. PubMed ID: 29448311
[TBL] [Abstract][Full Text] [Related]
54. Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT.
Earl H; Hiller L; Vallier AL; Loi S; McAdam K; Hughes-Davies L; Rea D; Howe D; Raynes K; Higgins HB; Wilcox M; Plummer C; Mahler-Araujo B; Provenzano E; Chhabra A; Gasson S; Balmer C; Abraham JE; Caldas C; Hall P; Shinkins B; McCabe C; Hulme C; Miles D; Wardley AM; Cameron DA; Dunn JA
Health Technol Assess; 2020 Aug; 24(40):1-190. PubMed ID: 32880572
[TBL] [Abstract][Full Text] [Related]
55. Prospective observational study on the impact of the 21-gene assay on treatment decisions and resources optimization in breast cancer patients in Lombardy: The BONDX study.
Zambelli A; Simoncini E; Giordano M; La Verde N; Farina G; Torri V; Colombo G; Piacentini G; Fotia V; Vassalli L; Pugliese P; Poletti P; Caremoli ER; Tondini C
Breast; 2020 Aug; 52():1-7. PubMed ID: 32325372
[TBL] [Abstract][Full Text] [Related]
56. MammaPrint guides treatment decisions in breast Cancer: results of the IMPACt trial.
Soliman H; Shah V; Srkalovic G; Mahtani R; Levine E; Mavromatis B; Srinivasiah J; Kassar M; Gabordi R; Qamar R; Untch S; Kling HM; Treece T; Audeh W
BMC Cancer; 2020 Jan; 20(1):81. PubMed ID: 32005181
[TBL] [Abstract][Full Text] [Related]
57. The budget impact of utilizing the Oncotype DX Breast Recurrence Score test from a US healthcare payer perspective.
Berdunov V; Laws E; Cuyun Carter G; Luo R; Russell C; Campbell S; Force J; Abdou Y
J Med Econ; 2023; 26(1):973-990. PubMed ID: 37466220
[TBL] [Abstract][Full Text] [Related]
58. 21-Gene Recurrence Score and Adjuvant Chemotherapy Decision for Breast Cancer Patients with Positive Lymph Nodes.
Tong Y; Wu J; Huang O; He J; Zhu L; Chen W; Li Y; Chen X; Shen K
Sci Rep; 2019 Sep; 9(1):13123. PubMed ID: 31511599
[TBL] [Abstract][Full Text] [Related]
59. Clinical utility of genetic signatures in selecting adjuvant treatment: Risk stratification for early vs. late recurrences.
Hayes DF
Breast; 2015 Nov; 24 Suppl 2():S6-S10. PubMed ID: 26238437
[TBL] [Abstract][Full Text] [Related]
60. Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer.
Albanell J; González A; Ruiz-Borrego M; Alba E; García-Saenz JA; Corominas JM; Burgues O; Furio V; Rojo A; Palacios J; Bermejo B; Martínez-García M; Limon ML; Muñoz AS; Martín M; Tusquets I; Rojo F; Colomer R; Faull I; Lluch A
Ann Oncol; 2012 Mar; 23(3):625-631. PubMed ID: 21652577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]